WEBULL
WebtradeDownload

Inspire Medical Systems (INSP) And The Valuation Debate Following Its Inspire V Delay

Simply Wall St · 2d ago

Recent sharp price moves in Inspire Medical Systems (INSP) have shifted attention to whether the current share level aligns with its cash generation, as suggested by a fresh Discounted Cash Flow valuation review.

Recent trading has been volatile for Inspire Medical Systems, with a 1-day share price return that declined 2.48% but a 90-day share price return up 70.73%. The 1-year total shareholder return is down 9.06% and the 5-year total shareholder return is down 71.84%, suggesting short-term momentum has picked up even as longer-term holders remain significantly under water.

Capitalize on the volatility around Inspire Medical Systems by comparing it with a hand picked 33 high quality undervalued stocks that currently pair solid fundamentals with more modest valuations.

Bulls point to Inspire Medical Systems’ sleep apnea niche and projected cash flows in the low to mid US$100 million range. Bears focus on volatile returns and a richer share price. Which case does the DCF work support?

Most Popular Narrative: 20% Overvalued

At a last close of $72.75, Inspire Medical Systems trades above the most followed narrative fair value of $60.40, which frames the current enthusiasm against more conservative cash flow assumptions and reimbursement risk.

The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues. As these barriers resolve, procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent up demand is realized.

See why 9 investors see Inspire Medical Systems as 20% overvalued.

Result: Fair Value of $60.40 (OVERVALUED)

Still, the thesis around Inspire Medical Systems can unravel if coding and reimbursement remain messy and if competition in hypoglossal nerve stimulation steadily chips away at procedure volumes.

Find out about the key risks to this Inspire Medical Systems narrative.

Another View on Inspire Medical Systems Valuation

The narrative fair value of $60.40 paints Inspire Medical Systems as 20% overvalued, yet the SWS DCF model tells a different story. On that cash flow view, INSP at $72.75 screens as good value, with the share price about 16% below an estimated $86.74 future cash flow value. Which lens should carry more weight for you?

Look into how the SWS DCF model arrives at its fair value.

INSP Discounted Cash Flow as at Sep 2026
INSP Discounted Cash Flow as at Sep 2026

Next Steps

Mixed messages on Inspire Medical Systems valuation and sentiment are clear, so move quickly, review the underlying data yourself and weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Inspire Medical Systems?

If Inspire Medical Systems has your attention, do not stop here. Put the same discipline to work across other opportunities using focused screeners built from real fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.